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Konstantinos Antonopoulos, MD, John D. Kakisis, MD, and Christos D. Liapis, MD, Athens, Greece
Background: Anatomic factors may limit the application of stent grafts for the treatment of arterial aneurysms. Flow-
diverting stents (FDSs) are specially designed to reduce flow velocity in the aneurysm sac and promote thrombosis while
maintaining flow in the main artery and branch vessels. FDSs include the Pipeline Embolization Device (ev3, Plymouth,
Minn), the SILK Arterial Reconstruction Device (Balt Extrusion, Montmorency, France), and the Cardiatis Multilayer
Stent (Cardiatis, Isnes, Belgium). The first two have been mainly used for the treatment of intracranial aneurysms. The
aim of this study was to review the current role of FDSs in the treatment of extracranial arterial aneurysms.
Methods: A systematic electronic health database search was conducted using PubMed, Ovid, Medline, and the Cochrane
Database on all accessible published articles through March 2012. An additional search for abstracts presented in
international congresses for vascular surgery was also performed. Full-text articles and abstracts were analyzed separately
due to the heterogeneity of the data.
Results: Results of the use of FDSs in arterial aneurysms were reported in 12 full-text articles including 35 patients (26
men, age 65.4) with 38 aneurysms. The aneurysms were located in the hepatic (n  12), splenic (n  6), renal (n  5),
celiac (n 4), superior mesenteric (n 3), subclavian (n 2), gastroduodenal (n 1), and popliteal arteries (n 1) and
in the descending thoracic (n  1), suprarenal (n  1) and infrarenal aorta (n  2). The 30-day mortality was 5.7% (2 of
35 patients). Three stent thromboses occurred (8.3%), none of them with clinical consequences. Thirty patients with 33
aneurysms and patent FDSs were monitored for an average of 9.2 months. Thrombosis occurred in 90.6%, and volume
reduction was observed in 81% of the aneurysms. No branch vessel occlusion occurred. Twelve abstracts were identified,
including 133 patients (mean age, 64.7 years). They included 62 peripheral, 28 visceral, and 43 abdominal and
thoracoabdominal aneurysms. The Cardiatis Multilayer Stent was used in all cases. Thrombosis was achieved in all but
two peripheral and visceral aneurysms. Volume reduction was observed in 82.7%, and no branch vessel occlusion
occurred. In aortic aneurysms, better results regarding aneurysm thrombosis, reduction of the volume, and patency of
collateral branches were reported at 12 months rather than at 6 months postoperatively. No aneurysm rupture has yet
been described.
Conclusions: Initial clinical experience with the use of FDSs in the treatment of visceral and peripheral aneurysms yielded
satisfactory results in technical success, aneurysm thrombosis and shrinkage, and in patency of branch vessels. The results
in aortic aneurysms are still under investigation. No aneurysm rupture has yet been described. There is a significant
incidence of FDS thrombosis. Volume reduction of the aneurysm is a clearer evidence of the clinical success after
treatment with FDSs than aneurysm thrombosis. ( J Vasc Surg 2012;56:839-46.)
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oComplex peripheral aneurysm anatomy, with major
branches in the immediate vicinity or arising from the
aneurysm, may impede endovascular management with
conventional stent grafts. Treatment options in such cases
are limited to fenestrated or branched stent grafts, hybrid
procedures, or open surgery with reimplantation of major
branches. Flow-diverting stents (FDSs) are specially de-
signed to reduce the flow velocity vortex within the aneu-
rysm and improve laminar flow in the main artery and
surrounding branches. Theoretically, FDSs could treat an-
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The principle of the FDS represents a true revolution in
he management of arterial aneurysms. An FDS is placed in
he parent artery with the target to reduce blood flow in the
neurysm sac to the point of stagnation, promoting gradual
hrombosis and neointimal remodeling, while maintaining
utflow in the side branches and perforators. To under-
tand the mechanism by which an FDS can cause aneurysm
hrombosis, the hemodynamics within the sac must be
tudied. For an aneurysm without collaterals, blood flow-
ng into the sac generates vortices. As these flow perturba-
ions progress, they become stronger until they reach the
neurysm outlet. These continuous movements induce
tress in the arterial wall.
When an FDS is placed in the aneurysm, stent geometry
educes the flow velocity within the aneurysm vortex while
mproving laminar flow in the main artery.1 Computation
emodynamics suggests that a stent with an overall porosity
f 50% to 70% (30%-50% metallic coverage) will signifi-
antly reduce the inflow rate into an aneurysm.2 Optimal
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September 2012840 Sfyroeras et alflow modulation through the layers is reached with a 65%
mean porosity. Secondary to this porosity level, when an
aneurysm is bridged, the stent laminates the blood flow by
pressure drop. Using particle image velocimetry, Augs-
burger et al3 demonstrated that velocity in the sac decreases
by an average of 88%. Arterial branching is characterized by
a change in flow direction, which induces disturbances at
the inlet and results in turbulence. With a traditional stent
in place, the vortex persists; however, a multilayer FDS
laminates the flow and eliminates the vortex.1
The FDSs currently available include the Pipeline Em-
bolization Device (PED; ev3, Plymouth, Minn), the SILK
Arterial Reconstruction Device (Balt Extrusion, Montmor-
ency, France), and the CardiatisMultilayer Stent (Cardiatis,
Isnes, Belgium).
The PED. The PED is a self-expanding, microcath-
eter-delivered device. It is a mesh tube of woven wire, made
of 25% platinum and 75% cobalt-nickel alloy, designed to
provide 30% to 35% metal coverage of the inner surface of
the target vessel, with a pore size of 0.02 to 0.05 mm2 at a
nominal diameter.4 The area of coverage provided by the
PED is approximately three times more than other com-
monly used intracranial stents. Sizes for vessel diameters
from 2.5 to 5 mm are available. The PED has been used for
the management of large, giant, wide-necked, and fusiform
intracranial aneurysms by reconstructing the parent artery
and restoring its natural course, with or without the use of
adjunctive embolic devices. The PED is attached to a
pusher wire, which has a platinum coil tip that extends 15
mm beyond the distal edge of the device. The PED is
delivered with a 3F (0.027-inch internal-diameter micro-
catheter) that requires a 6F guide catheter support. Once
positioned across the aneurysm, the delivery wire is held while
the distal one-third to one-half of the PED is carefully un-
sheathed. Once the unsheathed segment begins to expand,
the distal end is released by clockwise rotation of the delivery
wire. The proximal segment of the PED can then be de-
ployed,mainly through the application of forward pressure on
the delivery wire, supplemented by unsheathing.4
The SILK flow diverter. Another flow-modifying
device, the SILK flow diverter (SFD), is a flexible, self-
expanding device consisting of a braided mesh cylinder
with flared ends, composed of 48 nickel-titanium (nitinol)
alloy and platinummicrofilaments of35 m, designed to
provide 35% to 55%metal coverage of the internal diameter
of the target vessel, with a pore size of 110 to 250 m2.
Sizes for vessel diameters range from 3.5 to 4.25 mm. The
insertion technique involves deploying the distal tip of a
delivery microcatheter to the aneurysm and then pushing
the SFD to the tip of the delivery wire to which it is
attached. The system is then aligned with the aneurysm,
and the SFD is deployed by unsheathing it from the con-
straint of the microcatheter. This involves a combination of
pushing the delivery wire and retrieving the microcatheter
to allow the SFD to expand and to compensate for any
resulting foreshortening. The SFD can be retrieved into the
microcatheter and removed or repositioned when80% of ats length has been extruded. No retrieval is possible
hereafter.4
The Cardiatis Multilayer Stent. The Cardiatis Mul-
ilayer Stent is a tubular, self-expanding stent consisting of
ultilayer braided wires made of a cobalt alloy. It is avail-
ble in diameters from 6 to 16 mm for peripheral vessels
nd is delivered through a 6F to 12F sheath. Diameters for
ortic aneurysms range from 20 to 45 mm, and delivery is
hrough an 18F to 20F sheath. The radiopaque delivery
ystem consists of a guiding catheter. For peripheral use, the
elivery system can accommodate a 0.018-inch guidewire,
nd the stent can be removed or repositioned when 80%
f its length has been extruded. No retrieval is possible
hereafter. Access for the stent is preferentially from the
emoral artery, and it is advanced endoluminally under
ngiographic visualization to the desired lesion site. When
he deployment site is reached, the top of the delivery
ystem is placed a few centimeters above the target lesion
ite. This is done so that the position of the stent can still be
djusted while it is partially opened. To begin stent deploy-
ent, the metallic pusher is slowly pushed with the sheath
xed under radioscopy, and the multilayer stent begins to
e released. If necessary, the positioning can be adjusted by
etrieving the metallic pusher and the sheath together. The
eployment is then continued by pulling the sheath gently
nd progressively toward the fixed position of the metallic
usher. After full stent deployment, the pusher is pulled
ack in its initial position so that the atraumatic tip comes in
ront of the outer sheath. Finally, the delivery system is
emoved under radioscopy.
The PED and SFD were originally developed for the
ndovascular treatment of intracranial aneurysms. By 2010,
hese two FDSs had been used to treat 2500 intracranial
neurysms, including wide-necked, fusiform, large, and
iant unruptured intracranial aneurysms. Treatment of
hese lesions is associated with a 5% to 10% permanent
ajor morbidity and mortality.4 The Cardiatis Multilayer
tent is mainly designed for peripheral, visceral, and aortic
neurysms and has been approved for peripheral aneurysm
anagement in European countries since May 2009. The
im of this study is to review literature for the current role of
DSs in the treatment of extracranial arterial aneurysms.
ETHODS
A systematic electronic health database search was con-
ucted using PubMed, Ovid, Medline, and the Cochrane
atabase for all accessible articles published throughMarch
012. The keywords were multilayer or flow diverting or
ow diversion or flow diverter and stent, or multilayer flow
odulator, or Pipeline embolization device, or SILK flow
iverter, or Cardiatis Multilayer Stent. The initial database
earch revealed 120 publications; of these, 36 were experi-
ental or irrelevant, and 66 reported the results of FDS use
n intracranial aneurysms. One article was a commentary.
f the remaining 17 publications, one was a review article5
nd four were from the same author or institution and
eported the same material.6-9 Two were included in the
nalysis.7,9 Of 14 articles that we considered, 12 reported
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Volume 56, Number 3 Sfyroeras et al 841the use of FDSs in arterial aneurysms (Table I),1,7,9-18 one
in thoracoabdominal dissection,19 and one in carotid blow-
out syndrome.20 The full texts of these articles were re-
trieved and reviewed. Data on patient age, location of the
aneurysms, number and size of the stents, antiplatelet ther-
apy, follow-up time, branch vessel occlusion, aneurysm
thrombosis and diameter decrease, and stent occlusion
during follow-up were collected and summarized (Table I).
In a second step, we searched for oral presentations and
abstracts presented in international congresses. Oral pre-
sentations of the following congresses were searched: Soci-
ety for Vascular Surgery Annual Meeting: 2011 (previous
congresses were not available online); European Society for
Vascular Surgery Annual Meeting: years 2009, 2010, and
2011; the VEITH Symposium: years 2009, 2010, and
2011; Transcatheter Cardiovascular Therapeutics: years
2009, 2010, and 2011; International Congress: 2011 (pre-
vious congresses were not available online); and Cardiovas-
cular and Interventional Radiological Society of Europe:
years 2009, 2010, and 2011. All available abstracts were
collected and reviewed. Abstracts written by identical au-
thors or institutions were studied in detail and excluded if
necessary to prevent duplication. We identified 17 ab-
stracts.21-37 Three reported the results of the Italian Reg-
istry of Cardiatis Procedures supported by the Italian Soci-
ety of Vascular and Interventional Radiology,21-23 and the
most recent was included in the analysis.23 Five abstracts
came from the French group by Henry et al.25-28 The most
recent abstract reporting the results of the multilayer stent
on peripheral aneurysms27 and reporting on thoracoab-
dominal and abdominal aortic aneurysms were consid-
ered.28 Nine more abstracts by different groups were in-
cluded in the analysis (Table II).29-37
A separate analysis for full-text articles and abstracts was
conducted due to the heterogeneity of the data.
RESULTS
Full-text articles. Fourteen full-text articles were
identified and are included in this systematic review. Twelve
reported the results of the use of FDSs in the endovascular
repair of 38 arterial aneurysms (Table I) in 35 patients (26
men, nine women) who were a mean age of 65.4 years
(range, 16-81 years). Of these 38 aneurysms, 31 were
located in the visceral vessels, including the hepatic (n 
12), renal (n 5), splenic (n 6), celiac (n 4), superior
mesenteric (SMA; n  3), and gastroduodenal (n  1)
arteries. One aneurysm was located in the popliteal artery.
The aneurysms in three patients were located in the tho-
racic or the abdominal aorta. Four aneurysms, located in
the subclavian arteries bilaterally and the suprarenal and
infrarenal aorta, were treated in a 48-year-old HIV-positive
patient.
Most patients were at high risk for open repair, and
operations were performed under local anesthesia. Techni-
cal success was achieved in all cases. The Cardiatis Multi-
layer Stent was used in all but two patients. The SFD was
used in an SMA aneurysm12 and the PED in a splenic artery
aneurysm.15 6Two of the 35 patients died, for a perioperative mor-
ality of 5.7%. One patient died of pulmonary embolism 24
ours after the procedure and another died of myocardial
nfarction on day 4. Postoperative antiplatelet therapy is
escribed in Table I. There were three 30-day stent occlu-
ions in the 33 surviving patients (36 aneurysms; incidence
f stent thrombosis, 8.3%) involving three Cardiatis Multi-
ayer Stents deployed in SMA, splenic, and hepatic artery
neurysms.7,10 The SMA stent thrombosed because of
oor runoff, the splenic artery stent thrombosis was attrib-
ted to the patient’s poor compliance with dual-antiplatelet
herapy,10 and the reason for the hepatic artery stent occlu-
ion is unknown.7 In all cases, there were no clinical se-
uelae for the patients. Thirty patients with 33 aneurysms
nd patent FDSs were monitored for an average of 9.2
onths. Follow-up was performed with computed tomog-
aphy (CT) angiography in all cases. The stents do not
ffect imaging interpretation. During follow-up, all branch
essels originating from or near the aneurysm and covered
y the FDS remained patent. There was no FDS thrombo-
is after 30 days. Aneurysm thrombosis occurred in 29 of 32
90.6%). Nonthrombosed aneurysms were located in the
MA, renal artery, and suprarenal aorta. Shrinkage was
bserved in 26 of 32 aneurysms (81%) during follow-up.
Three reports covered the use of FDSs to treat aortic
neurysms. These include a 16-year-old girl with a tuber-
ulous thoracoabdominal aneurysm,17 a 48-year-old HIV-
ositive patient with suprarenal and infrarenal aortic aneu-
ysms, without an established infectious cause,14 and an
1-year-old man with multiple comorbidities.16 The Car-
iatisMultilayer Stent was used in all patients. Patients were
onitored for 12 to 18 months, and all covered branch
essels remained patent. Aneurysm thrombosis was ob-
erved in three of four aneurysms and diameter reduction in
ll four aneurysms. The Cardiatis Multilayer Stent was also
sed to treat an aortic type B dissection with aneurysmal
ilatation in a 69-year-old man.19 This patient had been
perated on 4 years earlier for a type A dissection with left
idney malperfusion. During follow-up, he presented with
neurysmal dilatation of the descending thoracic aorta.
hree re-entry vessels were feeding the false lumen. The
roximal was in the left subclavian artery and the distal at
he origin of the visceral arteries. The aorta was covered
rom the left subclavian artery to the abdominal aorta under
he renal arteries. Follow-up CT imaging at 3 months
emonstrated false-lumen thrombosis with aortic diameter
eduction.19
Finally, a 61-year-old woman with history of nasopha-
yngeal carcinoma and carotid blowout syndrome under-
ent endovascular treatment using a PED; however, this
reatment was not successful. Rebleeding occurred 2 days
ater and a second PED was inserted. She died of a massive
erebral infarction 2 months later, probably related to
omplicated in-stent thrombosis.
Published abstracts. Twelve abstracts presented at
nternational congresses were included in the analysis (Ta-
le II). An FDS was used to treat 133 patients (mean age,
4.7 years).
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September 2012842 Sfyroeras et alPeripheral and visceral aneurysms. Sixty-two pe-
ripheral aneurysms were managed; however, no informa-
tion was provided on the location for 35. Of the 27
peripheral aneurysms with location information, there were
21 iliac aneurysms (one pseudoaneurysm), four popliteal,
one femoral, and one subclavian.
Multilayer stents were also used in 28 visceral aneu-
rysms, including the renal artery (n 6), the SMA (n 2),
and the common hepatic artery (n  1). No information
was given on the location of the other 19 visceral aneu-
rysms. Technical success was achieved in all cases. Patients
were monitored for 1 to 30 months, and no branch vessel
occlusion was reported. In all but two patients, aneurysm
thrombosis was achieved at the last follow-up.
Volume reduction was observed in 24 of 29 aneurysms
(82.7%). Diameter reduction was observedmore frequently
with longer follow-up. Ruffino et al23 reported that 33 of
47 of the aneurysms decreased in diameter at 6 months and
21 of 26 at 12 months.23 No stent thrombosis was re-
ported.
Aortic aneurysms. The stents in 43 cases were de-
ployed in the aorta to treat 37 thoracoabdominal aneu-
rysms, five abdominal aortic aneurysms, and one penetrat-
ing aortic ulcer with rupture. In the largest clinical series,
presented by Vaislic et al,37 22 patients (18 men; mean age,
72 years) were treated using the Cardiatis Multilayer Stent
at nine centers in France. All patients had American Society
of Anesthesiologists score 3, with a mean aneurysm di-
ameter of 69.4 mm (range, 55.5-87 mm) and a mean
length of 257 mm (range, 174-343 mm). Ten aneurysms
Table I. Full-text articles reporting on the results of flow-
Author
Pts (n)
(No.)
Age
(years)
Aneurysms
(No.)
Henry1 1 78 1 RA
Ruffino10 19 60 19 5 SA
RA
Meyer11 1 74 1 RA
Shlomovitz12 1 64 1 SMA
Carrafiello13 1 60 1 CA
Ferrero7 4 64.7 4 HA,
Euringer14 1 47 4 L SC
inf
Abraham15 1 56 1 SA
Balderi9 3 NR 3 HA
Natrella16 1 81 1 Abdo
Benjelloun17 1 16 1 DTA
Pulli18 1 NR 1 PA
ASA, Acetylsalicylic acid; CA, celiac artery; DTA, descending thoracic aort
popliteal aneurysm; R, right; RA, renal artery; SA, splenic artery; SCA, sub
aCardiatis Multilayer Stent, Cardiatis, Isnes, Belgium.
bSILK Arterial Reconstruction Device, Balt Extrusion, Montmorency, Fran
cPipeline Embolization Device, ev3, Plymouth, Minn.were class 2 and 12 were class 3 according to the Crawford alassification. A mean of 2.54 stents were used per patient.
verall clinical success, as defined in terms of aneurysm
hrombosis, reduction of the lesion volume, as well as
ollateral branches patency, was achieved in 40% of 22
atients at 6 months.37 Seven patients were treated in
orocco. Clinical success was achieved in 83% at 12
onths.37 These 29 patients underwent a total of four
econdary interventions (13.7%), including intestinal resec-
ion due to celiac necrosis resulting from implant throm-
osis at day 15, secondary surgical revision at 8 months for
femoral pseudoaneurysm, and a type 1 endoleak that was
orrected using an additional multilayer stent proximally to
eal off the leak completely, followed by a secondary em-
olization of the left subclavian.37 In 12 more cases, re-
orted by Henry et al,28 no branch vessel occlusion was
etected and aneurysm thrombosis was achieved in all
ases.
ISCUSSION
Endovascular therapy of arterial aneurysms has signifi-
ant advantages because of its minimally invasive nature.
tent grafting is now in the third decade of its life. The use
f stent grafts is mainly limited by anatomic factors. Ana-
omic factors that preclude the use of stent grafts include
he presence of important collateral branch vessels in the
icinity or arising from the aneurysm. To move a step
orward in the treatment of patients with challenging anat-
my, several endovascular techniques have been developed,
ncluding fenestrated and branched endografts, the chim-
ey technique, and hybrid procedures. These techniques
ting stents in extracranial aneurysms
Location Stent Stents/size (n/mm)
CMSa 1/6  30
A, 3 CA, 2 SMA, 3
DA
CMS NR
CMS 1/6  30
SILKb 1/5.5  25
CMS 2/8  60, 7  60
CMS 4/NR
SCA, suprarenal aorta,
al aorta
CMS 2/12  50, 12  40,
1/12  60,
1/25  80
Pipelinec 1/5  20
CMS 3/8  60, 7  80,
10  40
l aorta (juxtarenal) CMS 1/28  100
suprarenal aorta CMS 3/16  40, 16  80,
16  80
CMS NR
follow-up; GDA, gastroduodenal artery; HA, hepatic artery; L, left; ; PA,
artery; SMA, superior mesenteric artery.diver
, 5 H
, 1 G
4
A, R
raren
mina
and
a; FU,
clavianre characterized by complexity, increased operation time,
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moreover, fenestrated and branched endografts are not
available “off the shelf” and usually require several weeks to
be ready.
Visceral artery aneurysms can be treated with surgical
exclusion, bypass, or simple ligation. Endovascular options
include stent graft exclusion and coil embolization. The
location of the aneurysm is an important factor for the
choice of treatment. An endovascular approach is prefera-
ble for aneurysms involving the splanchnic arteries.10 If
stent grafting is attempted, the collateral branches must be
covered. Aneurysms may be associated with elongation and
increased tortuosity of the vessel, a characteristic often seen
in splenic artery aneurysms. Deployment of a covered stent
may be technically unattainable in these aneurysms because
of the existing device limitations.
FDSs can represent a new alternative treatment option
for aneurysms given their unique characteristics. Up to
now, the largest published experience comes from use of
FDSs in the visceral aneurysms. The results are very encour-
aging, with a significant incidence of aneurysm thrombosis
and shrinkage during follow-up and without any branch
vessel occlusion. Regarding peripheral aneurysms, FDS
have been mainly used for the treatment of iliac, popliteal,
and subclavian aneurysms. In these anatomic areas, signif-
icant collateral branches have to be preserved, including the
internal iliac artery, the genicular arteries, and the vertebral
arteries, respectively.
Juxtarenal, suprarenal, and thoracoabdominal aneu-
rysms represent challenging aortic pathologies. Open sur-
Table I. Continued.
Antiplatelets
30- day
death
30-day stent
occlusion
ASA  clopidogrel for 1 month
then ASA
0 0/1
Dual for 1 month (ASA 100
mg  clopidogrel 75 mg or
ticlopidine) then ASA
1 2/18
ASA 100 mg  clopidogrel 0 0/1
ASA 100 mg  clopidogrel 0 0/1
Clopidogrel 0 0/1
NR 1 1/4
ASA 100 mg  clopidogrel 0 0/3
Clopidogrel 6 wks and ASA 0 0/1
NR 0 0
ASA 100 mg  clopidogrel 0 0
ASA 100 mg  clopidogrel for
1 month
0 0
Dual-antiplatelet therapy 0 0gery carries significant morbidity and mortality. Other op- tions include hybrid procedures and the chimney
echnique. Hybrid procedures, which involve surgical by-
ass grafting of the major aortic branches and endovascular
overage of the aortic aneurysm, are associated with a
0-day and in-hospital mortality incidence of 12.8%, 8.8%
enal failure, 7.5% spinal cord ischemia, 4.5% irreversible
araplegia, and 22.7% endoleak during follow-up.38
The chimney technique involves deployment of stents
nd stent grafts into the aortic visceral branches and deploy-
ent of an aortic endograft such that the proximal parts of
he visceral stents are placed parallel to the main aortic
ndoprosthesis (between the aortic stent and the aortic
all) and extend above (typical chimney technique) or
eyond (reversed chimney technique) it to ensure perfu-
ion. Endovascular procedures with the chimney tech-
iques are associated with 30-day mortality of 4.3%, 3.2%
troke, 2.1% myocardial infarction, and 11.8% renal func-
ion impairment.39 Because of the anatomic limitations of
he proximal aortic neck, long-term endograft durability
nd proximal fixation remain significant concerns and limit
idespread use of the method.39 Neither technique has
ffered a widely accepted solution in these difficult aortic
athologies.
The deployment of multilayer stents may overcome the
natomic limitations. Until now, multilayer stents have
een used in 45 patients for the treatment of aortic aneu-
ysms, including a patient with HIV and a teenaged girl
ith tuberculosis. Reported data suggest that 12-month
linical success is achieved in a significant proportion of
atients. Earlier, 6-month data may not be equally satisfac-
(m)
Branch vessel
occlusion
Aneurysm
thrombosis
Aneurysm diameter
decrease
6 0/1 1/1 1/1
16 pt) 0/16 14/16 12/16
5 0/1 1/1 0/1
2 0/1 1/1 1/1
2 0/1 1/1 1/1
2.4 0/2 2/2 1/2
8 0/4 3/4 4/4
0 0/1 1/1 1/1
2 0 3/3 3/3
2 0 1/1 1/1
8 0 1/1 1/1
R NR NR NRFU
6 (
1
1
1
1
2
1
1
1
Nory; however, Vaislic et al,37 with the largest series from
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September 2012844 Sfyroeras et alFrance, reported a 40% overall clinical success in 22 pa-
tients, as defined in terms of aneurysm thrombosis, reduc-
tion of the aneurysm volume, and collateral branches pa-
tency. The addition of patients with HIV and tuberculosis
may be confusing for the interpretation of the results;
however, these are two of the three full-text reports avail-
able for the use of multilayer stents in aortic aneurysms. We
still do not have the definite answers on the results of
multilayer stents in thoracoabdominal, suprarenal, and pa-
rarenal aneurysms; however, they seem to need time to
achieve optimal results in aneurysm thrombosis and shrink-
age. Therefore, their use in large aneurysms has to be done
with caution and the patients kept under close surveillance.
The traditional definition of endoleak and aneurysm
thrombosis may be not sufficient to describe clinical results
after the deployment of an FDS. Because the FDS is a flow
modulator and not a sealing stent graft, the goal is to
reduce pressure into the aneurysmal sac and promote
thrombosis. However, the image of a thrombosed aneu-
rysm in a postoperative CT scan does not preclude sac
pressurization, and the risk of rupture may not have been
eliminated.
Moreover, it is difficult to differentiate a type I en-
doleak, as classically defined, after implantation of a stent
graft with contrast leaking through the pores of an FDS.
Evidence of incomplete coverage of the proximal landing
zone with distal deployment of the FDS is suggestive of a
“true” type I endoleak. Clinical success is better described
with reduction of aneurysm volume, which reflects aneu-
rysm depressurization and prevention from rupture. A lack
of reduction with an FDS should raise suspicion of contin-
ued pressurization of the aneurysm. Aneurysm rupture was
reported after treatment of an intracranial aneurysm using
Table II. Published abstracts reporting on the results of fl
Author Congress Pts (No.) Age (yea
Ruffino18 TCT 2011 54 NR
Henry22 TCT 2011 32 61  8
Henry23 TCT 2011 10 61.4
Santoro24 CIRSE 2010 1 47
Hamada25 ESVS 2011 1 76
Butarrelli26 CIRSE 2011 1 NR
Burdi27 CIRSE 2011 1 63
Mauri28 CIRSE 2011 1 NR
Natrella29 CIRSE 2011 1 NR
Petrocelli30 CIRSE 2011 1 NR
Mauri31 CIRSE 2011 1 NR
Vaislic32 VEITH 2011 22b 72
7d NR
AAA, Abdominal aortic aneurysm; CIRSE, Cardiovascular and Intervention
NR, not reported; TAA, thoracoabdominal aneurysm; TCT, Transcatheter
aCardiatis Multilayer Stent, Cardiatis, Isnes, Belgium.
bPatients treated in France.
cOverall clinical success: aneurysm thrombosis, volume decrease, and all ves
dPatients treated in Morocco.the PED.40 No aneurysm rupture after FDS placement in rxtracranial aneurysms has been reported in the published
iterature; however, this may be a result of publication bias.
ore clinical studies and longer follow-up are needed to
nderstand the evolution of the aneurysms after their ex-
lusion using FDSs.
Another complication frequently encountered is FDS
hrombosis, which occurred in 8.3% of the cases. Fortu-
ately, when stent thrombosis occurred in SMA, splenic,
nd hepatic arteries, there were no clinical consequences for
he patients. Visceral arteries usually have a well-developed
ollateral network that sometimes prevents organ ischemia
n cases of acute occlusion. Particularly for the SMA stent
cclusion, the stent remained patent at the level of two
ollateral vessels, one feeding retrogradely the hepatic ar-
ery, previously occluded at its takeoff from the celiac trunk,
nd the other supporting the bowel vascular bed. The
atient did not experience any symptoms of hepatic infarc-
ion or bowel ischemia.10 The experience of the SFD stent
n intracranial aneurysms showed quite high delayed clinical
nd anatomic complication rates, with significant parent
rtery stenoses in 33%.41
Adequate antiplatelet therapy is important after deploy-
ent of an FDS.11,41 Dual-antiplatelet therapy was not the
tandard treatment in all patients. Poor compliance of a
atient with dual-antiplatelet therapy was the reason of a
plenic artery stent thrombosis10 However, other factors,
ike poor runoff, also predispose to stent thrombosis.10
ONCLUSIONS
Initial clinical experience with FDSs in the treatment of
isceral and peripheral aneurysms yielded satisfactory re-
ults in technical success, aneurysm thrombosis and shrink-
ge, and branch vessel patency. In aortic aneurysms, better
iverting stents in extracranial aneurysms
Aneurysms (No.) Location
54 35 peripheral, 19 visceral
32 20 iliac, 1 femoral, 41 popliteal, 6
renal, 1 mesenteric
10 6 TAAs, 4 AAAs
1 Subclavian artery
1 1 TAA (type II)
— Rupture of penetrating aortic ulcer
1 Common hepatic artery
1 Iliac pseudoaneurysm
1 Juxtarenal AAA
1 SMA pseudoaneurysm
1 TAA
227 22 TAAs (10 type II, 12 type III)
7 TAAs
iological Society of Europe; ESVS, European Society for Vascular Surgery;
ovascular Therapeutics.
tent.ow-d
rs)
al Rad
Cardiesults are achieved 12 months after the procedure rather
11
1
1
1
1
1
1
1
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Volume 56, Number 3 Sfyroeras et al 845than at 6 months. No aneurysm rupture after treatment
with an FDS has been described to date. There was a
significant incidence of FDS thrombosis. Larger clinical
series with longer follow-up will enlighten in the near
future the role of FDSs in aortic, splanchnic, and peripheral
aneurysms.
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